All they have to do is allow GS to prescribe cannabis and KNB share holders will be minted.
3 Likes
That should say GPs
They do already. Well, ish and you make a good point. I mean between you, me and lampost it is a when and not an if. Even with our current draconian Home Secretary progress is being made.
2 Likes
Germany to liberalise cannabis use and sale.
3 Likes
Getting high in Switzerland
2 Likes
This makes for good reading
Responding to the news, Niklas Kouparanis, CEO and co-founder of German cannabis company, Bloomwell Group, commented: “There were no big surprises from the Cabinet meeting, and now, one thing is clear: the largest European economy in the heart of the European Union is ushering in a new era for cannabis. The legislation presented today is a turning point for cannabis regulations in the EU, setting a positive example of what’s possible for the rest of Europe and the world.”
1 Like
Last link doesn’t work, takes you to the wrong article. It’s up there on the cannabis health news web site.
Can someone explain in real simple terms why the share chart is so up and down compared to other shares with go up then down. This one looks like a politician lie detector test
There are a number of factors, and to put them simply:
Kanabo shareholders and prospective shareholders are waiting to hear whether or not their vape tech gets a CE mark which means Kanabo can sell it in the EU. This new tech delivers a medical grade dosage.
Also, Kanabo spent a lot of money on a few things over the last year: the vape tech, a telehealth GP service, research and a supply model. They have impressively created a farm to patient company. The income is coming in but it will take time for prospective shareholders to have faith in the model.
And the current feeling towards UK shares, especially on AIM Market (which Kanabo are) is hugely negative. AIM companies are mainly new tech, mines, services and in the current high inflation sector investors are looking for safe, big companies, like Apple, Tesla, etc,.
However, Kanabo shares are starting to look very cheap. If the CE mark happens, considering the positive outlook for medical cannabis in europe then there is much to be positive about.
I’ve tried to be brief without missing anything out. As always, anyone else reading feel free to refine these notes (Geoff, the expert on this thread will have a good take).
2 Likes
Thankyou for taking time. Its just chart seems very erratic compared to alot other shares.
Are you referring to the daily chart which I agree does look like a conservative politician on a lie detector but is just the share price spread showing the buys and sells. I think the reason is with KNB you get a lot of tiny trades and not much movement in the SP, but when she moves it can be dramatic 
2 Likes
The likely role of big pharma in cannabinoid medicines over the next four years. With a look over previous M&A, Jazz being the most prominent. It’s a US focussed article but nevertheless useful to note, as these companies will be looking at Europe and especially Germany quite closely as legislation on use broadens.
1 Like
I sold my GW pharmaceutical shares for under a £1 
I won’t be making that mistake with Kanabo.
1 Like
Perhaps unrelated to market news but masthead on Kanabo store webpage mentions new stock incoming in September
It could just be the relax CBD cartridges which are currently sold out but I have been wondering about the sublingual spray they have talked about. Not long until September anyway.
1 Like
Also worth noting that HELD are probably harvesting nowish. Interesting to see how that fits into KAN picture.
When people catch on to the benefits of medical cannabis, I have an elderly neighbour who was not doing so well a couple of months ago, I make my own CBD products so gave him some. Yesterday he came to my door with a cheeky smile on his face asking for more, told me how it had worked wonders for him then looked at the sky like a kid and said it’s brighter 
I love watching how this stuff brings people back to life.
4 Likes